Skip to search formSkip to main contentSkip to account menu

IRX 2

Known as: IRX-2 
A cell-free mixture comprised of a variety of naturally-derived cytokines obtained from normal, unrelated donor lymphocytes with potential… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

cytokine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
GLOBAL OPTIMIZATION METHOD FOR DESIGN PROBLEMS
In structural design optimization method, numerical techniques are increasingly used. In typical structural optimization problems… 
Review
2010
Review
2010
Preclinical studies with IRX‐2 and thymosin α1 in combination therapy
Thymosin α1 (Tα1) is a 28 amino acid biologically active protein with pleiotropic immune enhancing activity. IRX‐2 is a primary… 
2010
2010
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
2007
2007
IRX‐2 and Thymosin α1 (Zadaxin) Increase T Lymphocytes in T Lymphocytopenic Mice and Humans
Abstract:  Mouse studies showed a synergy of thymosin α1 (Tα1) and a natural cytokine mixture (IRX‐2) in increasing T lymphocyte… 
2007
2007
Immunopharmacology of Thymosin α1 and Cytokine Synergy
Abstract:  Thymosin α1 (Tα1) is a 28 amino acid biologically active protein cleaved from positions 2–29 of a precursor protein… 
2007
2007
Immunopharmacology of thymosin alpha1 and cytokine synergy.
Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein cleaved from positions 2-29 of a precursor protein… 
2003
2003
Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
2000
2000
Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
OBJECTIVES To test the efficacy of a natural cytokine mixture (IRX-2), cyclophosphamide, indomethacin, and zinc to induce immune… 
1998
1998
Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
OBJECTIVE To induce tumor regression with immunotherapy and to characterize the histology. SETTING National Institute of… 
1998
1998
A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)